Statin Therapy and Breast Cancer Recurrence

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.

Related Content

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Natasha Bahri, MD, MS;Daneng Li, MD

December 30th 2024

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.